MMCM
CRSP icon

Murphy & Mullick Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Murphy & Mullick Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.54K Sell
120
-44
-27% -$2.32K ﹤0.01% 529
2026
Q1 		$7.8K Sell
164
-121
-42% -$6.38K 0.01% 499
2025
Q4 		$14.9K Hold
285
– – 0.01% 441
2025
Q3 		$18.5K Hold
285
– – 0.01% 395
2025
Q2 		$16K Buy
285
+97
+52% +$3.75K 0.01% 400
2025
Q1 		$6.4K Hold
188
– – 0.01% 489
2024
Q4 		$7.4K Buy
+188
New +$8.88K 0.01% 468

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Murphy & Mullick Capital Management's CRSP Position: Q2 2026 in Review

Murphy & Mullick Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 27% in Q2 2026, selling an estimated $2.32K and leaving 120 shares worth $6.54K. The position accounts for ﹤0.01% of the portfolio, ranked #529.

Murphy & Mullick Capital Management first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. The position peaked at $18.5K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Murphy & Mullick Capital Management held 120 shares of CRISPR Therapeutics worth $6.54K as of Q2 2026.
  • Murphy & Mullick Capital Management sold 44 CRISPR Therapeutics shares in Q2 2026, an estimated $2.32K.
  • CRISPR Therapeutics made up ﹤0.01% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #529 holding.
  • Murphy & Mullick Capital Management first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Murphy & Mullick Capital Management's CRISPR Therapeutics position peaked at $18.5K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.